SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin’s arm gets USFDA approval for generic Combivir tablets

31 Oct 2011 Evaluate

Pharma Major, Lupin’s US subsidiary - Lupin Pharmaceuticals, Inc. (LPI) has received tentative approval for its Lamivudine and Zidovudine tablets, 150 mg/300 mg from the United States Food and Drugs Administration (USFDA) for the company's abbreviated new drug application (ANDA) to market a generic version of Combivir tablets, 150 mg/300 tug of ViiV Healthcare.

Lupin's Lamivudine and Zidovudine tablets are the AB-rated generic equivalent of ViiV Healthcare's Combivir tablets, 150 mg/300 mg. Lamivudine - Zidovudine is a combination of two nucleoside analogue reverse transcriptase inhibitors and is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

According to IMS Health sales data, Combivir tablets, 150 mg/300 mg had annual US sales of approximately $295 million for the twelve months ending June 2011.

Lupin has a vibrant presence in the Indian pharmaceuticals market and has over the past several years made major strides in expanding its therapy portfolio. Lupin has a robust promotion and distribution setup along with a strong presence in various therapeutic areas, including the fast growing diabetes market.

Lupin Share Price

2244.00 -133.90 (-5.63%)
11-May-2026 11:38 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1876.90
Dr. Reddys Lab 1288.50
Cipla 1339.55
Zydus Lifesciences 947.20
Lupin 2244.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×